# International Advisory Board

## Terms of Reference

### About ADAPT SMART

The overall scope of ADAPT SMART (Accelerated Development of Appropriate Patient Therapies; a Sustainable, Multi-stakeholder Approach from Research to Treatment-outcomes) is to establish a neutral enabling platform for the coordination of MAPPs related activities within the Innovative Medicines Initiative and engage a dialogue with all relevant stakeholders.

Medicines Adaptive Pathways to Patients (MAPPs) seek to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product lifespan in a sustainable fashion.

The ADAPT SMART consortium assesses tools, methods, and evidence that help manage uncertainties of adaptive pathways. Where needed, the consortium will identify and recommend development (in IMI or other consortia) of new approaches, tools, training and resources in order to make MAPPs a reality.

### ADAPT SMART International Advisory Board

The International Advisory Board (IAB) will provide the ADAPT SMART consortium with external guidance on its strategic objectives and deliverables. IAB members’ experience and expertise reflect the consortium aspirations, connectivity with key stakeholders groups and desire to deliver results that would be relevant in different regions of the world.

### The tasks of the International Advisory Board

- Provide independent external advice on ADAPT SMART strategy and deliverables (including annual reports), in particular their relevance from a global medicines development, regulatory, patients and public, and health technology evaluation perspectives.
- Provide advice on communication strategy, publications and other communication tools.
- Assist ADAPT SMART in developing relationships with key international players relevant for the adaptive models debate and establishing an international vision on adaptive pathways.
- Advise on ex-European research programmes and potential opportunities for collaboration.
Members

The up to 10 members of the International Advisory Board represent perspectives of the following key stakeholders groups from pan-European or international levels from research intensive regions: patient perspective, regulatory practice, health technology assessment, pricing and reimbursement, clinical research, and communication/media.

Mode of operation

The International Advisory Board:

• Interacts with ADAPT SMART through the Navigator Group (consortium’s steering group)
• Is consulted in writing on all key deliverables – these written consultations can be complemented by teleconferences/webinars where necessary.
• Meets once a year face to face in the context of the ADAPT SMART annual meetings
• Agrees its recommendations and advice are made public by Navigator Group on the ADAPT SMART website (www.adaptsmart.eu)
• Is chaired by one of its members, for the term of the project
• Will review membership in case of extension of the project. To secure continuity, at least one third of the members will be invited to serve for more than one year.
• Will invite new members to join the IAB in consultation with existing members of the IAB
• May request their membership to be terminated at any time in writing, by email or letter to the Chair of the IAB.

Rules of engagement

• Members of the International Advisory Board will not receive a honorarium from the ADAPT SMART consortium or IMI.
• Reimbursement of travel and accommodation expenses for attending the annual face to face meeting can be provided where requested, and if booked according to ADAPT SMART travel rules.

Conflicts of interest and confidentiality

A member of the International Advisory Body shall not participate in any IAB discussion where a situation or circumstance of personal or professional nature can compromise his/her ability to provide advice and recommendations in the interest of best performing his/her objectives and tasks.

Members of the IAB shall respect, where necessary, the confidential character of the proceedings and shall protect any information whose disclosure could damage the interests of the ADAPT SMART consortium or IMI2 in general. In the event confidentially information is shared, Members of the IAB shall sign a declaration of confidentiality and non-conflict of interest to be provided to the IMI2 JU Programme Office.